Patent · US Active

RNAi modulation of the BCR-ABL fusion gene and uses thereof

US7994307B2 · kind B2 · utility

7Cited by

4References

15Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Philipp Hadwiger · Kulmbach, DE
Hans-Peter Vornlocher · Bayreuth, DE
Heiko Van Der Kuip · Herrenberg, DE

Key dates

Filing date	Jul 27, 2009
Grant date	Aug 9, 2011
Priority date	—
Expiry date	Jul 27, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/33
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.